-
Clinical Services.
-
Data Management, Biostatistics.
-
Innovative data collection tools, secured gateway, biosensors…
-
Tailor made applications
What We Do
PopsiCube is a Contract Research Organization (CRO) supporting the pharmaceutical, biotechnology, and medical device industries with clinical research services outsourced on a contract basis
We Innovate & Design
We are innovative and design our health future actively
PopsiCube is not just a CRO. We also act in collaborative projects in the area of the future of health care, like personalized and predictive medicine, and artificial intelligence where our combined expertise in clinical trials and new technologies have great applications
In a nutshell:
Quality Comes First
FOVEA obtained the ISO 9001 Certification of its Quality System on December 7th, 2000 thus becoming one of the very first CROs certified in France.
PopsiCube gives much importance to the delivery of Quality satisfying services to our clients, in compliance with the applicable regulations. Thus, the Quality Management System is considered as an essential topic in our organization in order to maintain quality in a continual improvement way.
PopsiCube was ISO 9001 Certified for its Quality System on December 7th, 2000 (1994 edition), thus becoming one of the very first certified CROs in France. PopsiCube is now ISO9001:2015 certified and subject to regular external audits.
Please check our Quality Policy and Management Commitment here.
Contact us for more information about our QMS.
Our History
Established in 2004, PopsiCube is an innovative independent contract research organization (CRO) fully owned by its founders.
At the beginning, PopsiCube was a clinical eTool company focusing on developing software for clinical research. Our expertise stems from many years of experience spent inside the largest CROs or pharmaceutical companies in both the clinical and IT aspects of Clinical Research.
We always considered IT as a valuable tool and as a way to improve and industrialize processes in Clinical Research.
In 2007, PopsiCube expanded its vision with the intent to become a full services Clinical CRO.
In 2010, we opened an office in Philadelphia (USA) to serve the North American market.
In 2014, Ni Hao ! PopsiCube China opened in Wuhan, Hubei province.
Also in 2014, PopsiCube bought Mission TEC, a niche CRO based in Toulouse, France. Mission TEC, created in 2002, provides In-Home and In-Hospital clinical research services.
In 2017, PopsiCube acquired FOVEA-GROUP, an early stage clinical CRO born in 1988. This acquisition expanded our senior management staff, and provides additional expertise in many therapeutic areas and referencing in several big size companies.
Today the PopsiCube-Fovea Head Office is located near Paris, with regional offices in Toulouse and Normandy – providing easy access to the most important population centers in France. We are supported by an international staff across the world through our various affiliates.
In addition, we offer worldwide reach to our clients through key external partnerships and strategic alliances, with partners in the Europe, Canada, and Asia.
The combination of an agile and flexible contract research organization (CRO), coupled with the ability to confidently manage very large projects allows us to move a project from its initial planning stage to recruitment with dramatic speed and cost efficiency.
Our Mission
Our mission is to accelerate the development of new treatments thanks to IT innovation and clinical trial management efficiency.
Working hand in hand with the study sponsors allows us to not only deliver the clinical trial effectively, on time and on budget, but also to leverage our in-depth expertise to ensure the clinical trial is designed with efficiency.
Our Goal
PopsiCube is an independent full service CRO which organizes and conducts clinical trials to test new molecules, devices or treatments in humans. As such, we aim at offering our clients an objective assessment of new treatments in the clinical setting.
About CRO Growth
Growth of the CRO sector is expected to hover between 6% and 7% over the next 5 years and should reach $66bn in 2027. The factors contributing to this growth include increasing R&D, outsourcing, M&A activity, patents expiration, as well as government organizations new assignment of projects to CROs.
Research Tax Credit Agreement
Qualified and Experienced Agents
Seniority and reliability of the team with a low level of turn-over: the guarantee for you to keep the same contacts all along your projects.
Best Offers
Cost effectiveness, price, and affordability.
Technology
We align process and technology so that you benefit from fast delivery and predictable outcomes.
